Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia

Current Medical Research and Opinion

Volumn 30, Issue 2, 2014, Pages 223-228

  Li, Juyi ^a   Wang, Xiufang ^a   Zhang, Zhaoqing ^a   Zou, Jili ^a   Chen, Yonggang ^a   Wang, Xiong ^a   Wu, Jinhu ^a  

^a TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

CYP2D6; Hyperlipidemia; Individualized therapy; Polymorphism; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; CYTOCHROME P450 2D6; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYP2D6 GENE; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; AGED; ANALYSIS; BLOOD; GENETIC POLYMORPHISM; GENETICS; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIAS; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SIMVASTATIN;

EID: 84893311505     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.858619     Document Type: Article

References (29)

1. Wang A, Yu BN, Luo CH, et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005;60:843-8
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
3. Bays H. Statin safety: An overview and assessment of the data-2005. Am J Cardiol 2006;97:6-26C
4. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191-9
5. Vickers S, Duncan CA, Chen IW, et al. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-45
6. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15
7. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001;70:546-51
8. Nordin C, Dahl ML, Eriksson M, et al. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet 1997;350:29-30
9. Geisel J, Kivisto KT, Griese EU, et al. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism. Clin Pharmacol Ther 2002;72:595-6
10. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56:120-4
11. Wang A. CYP3A4, CYP2C9, and HMG-CoA Reductase Enzyme Genetic Polymorphism and its Impact on the Lipid-Lowering Efficacy of Simvastatin. Central South University, 2005
12. Liao HW, Tsai IL, Chen GY, et al. Simultaneous detection of single nucleotide polymorphisms and copy number variations in the CYP2D6 gene by multiplex polymerase chain reaction combined with capillary electrophoresis. Anal Chim Acta 2013;763:67-75
13. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
14. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006;11:126-35
15. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526
16. Huang L, Song XM, Zhu WL, et al. Plasma homocysteine and gene polymorphisms associated with the risk of hyperlipidemia in Northern Chinese subjects. Biomed Environ Sci 2008;21:514-20
17. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13
18. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 allele nomenclature. Available at: Http://www.cypalleles.ki.se/cyp2d6.htm [Last accessed 10 June 2013]
19. Qin SY, Shen L, Zhang AP, et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 2008;92:152-8
20. Lei TW, Xu QZ, Wu N, et al. Research on CYP2D6. *10B gene polymorphism in Chinese Miao nationality. Chin J Public Health 2004;20:439-40
21. Lee SY, Sohn KM, Ryu JY, et al. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006;28:382-7
22. Nishida Y, Fukuda T, Yamamoto I, et al. CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6. *10. Pharmacogenetics 2000;10:567-70
23. Serin A, Canan H, Alper B, et al. The frequencies of mutated alleles of CYP2D6 gene in a Turkish population. Forensic Sci Int 2012;222:332-4
24. Wan YJ, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. Pharmacogenetics 2001;11:489-99
25. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 2006;24:381-5
26. Sachse C, Brockmö ller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95
27. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993;24:195-202
28. Zuccaro P, Mombelli G, Calabresi L, et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007;55:310-17
29. Nakamura K, Ariyoshi N, Yokoi T, et al. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun 2002;293:969-73